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Currently available drugs for treatment of Leishmania infections are highly toxic and drug resistance to
ﬁrst line therapies has been observed. New, safer and more effective drugs are urgently needed to
improve clinical resolution of the disease and reduce the risks associated with it. High-throughput
screening of new compounds against cultured promastigotes is easy to perform, but the results are poorly
predictive of in vivo efﬁcacy. Intra-macrophage amastigote models provide a better proxy of the clinically
relevant stage of disease and should be routinely implemented in the search for new anti-leishmanial
agents, despite being labor intensive.
This study describes the use of a duplex quantitative Reverse-Transcriptase PCR (qRT-PCR) for assess-
ment of drug activity against Leishmania intracellular amastigotes and their host cells. The assay simul-
taneously quantiﬁes Leishmania 18S ribosomal RNA and the human b2-microglobulin (b-2M) mRNA, used
for monitoring drug cytotoxicity and test performance. Accurate determination of parasite viability by
the newly developed qRT-PCR was conﬁrmed by parallel assessment of compound performance against
standard microscopy. Highly reproducible anti-leishmanial activities were obtained with a set of struc-
turally- and pharmacologically-diverse compounds, whose toxicity against host cells correlated with a
low b-2M ampliﬁcation. Sensitive and versatile, this duplex qRT-PCR offers a valuable tool for assessment
of drug activities against Leishmania amastigotes and their host cells.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Leishmaniasis is caused by protozoan parasites of the genus
Leishmania. In humans, the parasite causes a wide spectrum of clin-
ical syndromes, from self-healing skin ulcers to severe, life-threat-
ening disease, following visceralization in the lymphoid organs.
Approximately 12 million people are currently infected with the
disease and an estimated 2 million new cases occur each year, of
which 1.5 million of cutaneous leishmaniasis and 0.2–0.4 million
of visceral leishmaniasis (Alvar et al., 2012). Chemotherapy re-
mains the only effective way to treat all forms of disease, but cur-rent drugs are toxic, expensive and increasingly inefﬁcacious due
to parasite resistance, compelling the search for new anti-leish-
manial agents (Grogl et al., 1992; Croft et al., 2006a; Monzote,
2009).
Development of new drugs relies on the screening of large num-
bers of compounds, for which robust and highly performing assays
are required. Axenic, insect-stage promastigotes provide a simple
model for evaluation of anti-leishmanial drug activity at high-
throughput, but the resulting data have little value in animals,
due to the metabolic and ecological differences that distinguish
promastigotes from the mammalian amastigote stage (Croft
et al., 2006b; Gupta and Nishi, 2011). Macrophages carrying
Leishmania amastigotes resemble the clinically relevant phase of
disease, and have therefore been recognized as most predictive of
clinical efﬁcacy (Gupta and Nishi, 2011; Seifert, 2011). Tradition-
ally, drug activity against this stage is measured by microscopy
counting of the percentage of infected macrophages and the num-
ber of amastigotes therein, a method which is labor-intensive and
time-consuming (Sereno et al., 2007). In addition, establishment of
parasite viability through staining procedures is difﬁcult and often
subjective, leading to potential inaccuracies in potency estimation
(Gupta and Nishi, 2011). Recent introduction of reporter gene
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Ashuthos et al., 2005; Buckner and Wilson, 2005; Lang et al.,
2005) has overcome this problem, but the use of parasite-
recombinant markers that is associated with these techniques re-
quire stringent culturing conditions and prevent from assessing
macrophage viability. Automated image-based assays provide a
valuable alternative in this respect, enabling high-content
examinations of compound activity against both Leishmania
amastigotes and their host cells (Siqueira-Neto et al., 2012). Their
implementation across non-dedicated facilities, however, remains
limited, due to the sophisticated equipment required. PCR
technology is nowadays widely available and has proven useful
in monitoring anti-leishmanial drug efﬁcacy at both in vitro and
in vivo level (Dorlo et al., 2011; Sundarshan et al., 2011). Several
real-time quantitative PCR (qPCR) assays have been developed
for detection of viable Leishmania parasites and assessment of drug
performance (Reimão et al., 2001; Ordóñez-Gutiérrez et al., 2009;
Gomes et al., 2012), either through SYBR Green or ﬂuorogenic
probe technology. Importantly, these tests lacked an internal
control that surveyed for test performance and monitored drug
toxicity against the mammalian host cells.
The present study validates the use for drug screening purposes
of a duplex Reverse-Transcriptase qPCR (qRT-PCR) simultaneously
assessing for toxicity against Leishmania intracellular amastigotes
and their host cells. Ampliﬁcation of Leishmania-speciﬁc 18S
ribosomal RNA was combined with the human b2-microglobulin
(b2-M) mRNA, producing a sensitive and highly accessible tool to
accurately measure anti-proliferative effects against the relevant
stage of leishmaniasis.2. Materials and methods
2.1. Compounds
Amphotericin B (Calbiochem, Nottingham, UK), miltefosine,
paromomycin, H-89 dihydrochloride hydrate and imipramine
hydrochloride (all from Sigma–Aldrich Co., St. Louis, USA) were
used for pharmacological validation of the qRT-PCR, alongside with
the newly synthesized compounds (VUF11852, VUF11854,
VUF11856, VUF11857 and VUF13577) kindly provided by Dr. K.
Orrling (VU University, Amsterdam, The Netherlands) within the
framework of a collaborative project (T4-302, Ti Pharma) for devel-
oping new phosphodiesterase inhibitors as potential anti-leish-
manial drugs (Orrling et al., 2012). Drug stock solutions (10 mM)
were constituted in water, ethanol or DMSO, according to the com-
pound solubility. Further dilutions of the drugs were performed in
culture medium, possibly supplemented with the corresponding
solvent to yield equal medium composition over the dilution ser-
ies. For infected macrophages used as untreated controls (without
drugs), DMSO, ethanol or water were added to the culture medium
at the same concentrations as for the drugs.
2.2. Leishmania promastigotes
Leishmania donovani 1S promastigotes (MHOM/SD/68/1S) were
maintained axenically at 27 C, by serial passages in RPMI 1640
medium (Gibco, Bleiswijk, The Netherlands) supplemented with
25 mM HEPES, 2 mM L-glutamine and 10% fetal calf serum (FCS,
Sigma–Aldrich Co.).
2.3. Leishmania intracellular amastigote model
THP-1 cells (human acute monocyte leukemia cell line) were
cultured in RPMI 1640 medium supplemented with 25 mM HEPES,
2 mM L-glutamine, 10% FCS, penicillin (50 IU/ml) and streptomycin(50 lg/ml), to a density of 500,000 cells/ml. Cells (100 ll) were
transferred to a 96-well culture plate for later testing by PCR and
to a Lab Tek 16-well chamber-slide (Nunc, Waltham, USA) for
microscopy counting. Next, 100 ll of cell culture medium contain-
ing 20 ng/ml of phorbol myristate acetate (PMA, Sigma–Aldrich
Co.) were added to each well in order to differentiate the THP-1
cells into adherent macrophage-like cells. After 2 days of incuba-
tion at 37 C, 5% CO2, cells were washed 3 times with culture med-
ium to remove non-adherent cells. Infection of macrophages was
performed with 200 ll of Leishmania donovani 1S promastigotes
at a density of 2.5 million parasites/ml. After 18 h of incubation
at 37 C, 5% CO2, cells were washed to remove excess of promastig-
otes and further incubated for 3 days with culture medium con-
taining the appropriate concentration of test compound.
Untreated (containing no drugs) and uninfected (containing no
parasites and no drugs) controls were included in all drug experi-
ments using the same culture medium. Two independent experi-
ments testing a total of 10 different compounds were performed
in triplicate for PCR and in duplicate for microscopy.
2.4. Analysis of intracellular amastigote content by microscopy
After 72 h of incubation at 37 C, 5% CO2, the slides were re-
moved from the culture chambers, methanol-ﬁxed and Field-
stained. Their examination was performed with a light microscope
(Leica, Rijswijk, The Netherlands), using a 100 objective. Results
were expressed by mean of the parasite index (percentage of in-
fected macrophages mean number of amastigotes per macro-
phage), after examining a minimum of 100 macrophages per
sample. Infection was judged to be adequate if more than 70% of
the macrophages in the untreated control were infected.
2.5. Analysis of intracellular amastigote content by qRT-PCR
After removal of culture medium, 0.75 ml of Trizol (Invitrogen,
Bleiswijk, The Netherlands) was added to all wells for cell lysis and
the lysates transferred to 1.5 ml tubes. RNA was Trizol-extracted
and puriﬁed according to manufacturer’s instructions. Residual
DNA was further removed from all extracts by DNase digestion
with Turbo DNase (Ambion, Invitrogen), performed according to
the manufacturer’s instructions. A duplex qRT-PCR was performed
for quantiﬁcation of both Leishmania and human RNAs. The assay
targeted the 18S small sub unit (SSU) rRNA conserved in Leish-
mania spp. and the human b-2M mRNA. The Leishmania qRT-PCR
consisted of the forward primer 50-CCAAAGTGTGGAGATCGAAG-
30, the reverse primer 50-GGCCGGTAAAGGCCGAATAG-30 and the
probe 50-6FAM-ACCATTGTAGTCCACACTGC-30-NFQ conjugated to
a minor groove binder (MGB) to increase the binding afﬁnity of
the probe to the target (van der Meide et al., 2008). For b-2M,
the sense primer 50-GGCTATCCAGCGTACTCCAA-30 and the anti-
sense primer 50-GATGAAACCCAGACACATAGCA-30 located within
exon 1 and 2 (Mahoney et al., 2004) were used, together with
the ﬂuorescent probe 50-GATGAAACCCAGACACATAGCA-30, labeled
at the 50-terminus with the reporter dye Texas red and at the
30-terminus with the quenching dye. Tenfold lower quantities of
b-2M primers and probe with respect to the Leishmania 18S ones
were added to the reaction mixture, to avoid sensitivity of the
18S PCR being affected by competition for b-2M ampliﬁcation.
For the PCR reaction, 1.25 ll of isolated RNA sample was added
to 11.25 ll of ampliﬁcation mix (Bio-Rad iScriptTM One-Step
RT-PCR Kit for Probes, Hercules, USA) containing 2 PCR reaction
reagent (20 mM Tris–HCl (pH 8.4), 50 mM KCl, 0.8 mM dNTPs,
3 mMMgCl2 and 0.6 U/ll iTaq DNA polymerase), reverse transcrip-
tase, 0.8 lM of each Leishmania primer and 0.2 lM of FAM-MGB
probe, 80 nM of each b-2M primer and 20 nM of probe. Ampliﬁca-
tion and real-time measurement were performed with the CFX-1
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5 min at 95 C followed by 45 cycles, each consisting of 30 s at
95 C and 45 s at 60 C.
Toxicity thresholds for macrophage viability were set according
to 90% cytotoxic concentrations (CC90) of tested drugs, correspond-
ing to a 3 Ct value increase in b-2M ampliﬁcation over the controls.
Consistent reduction of b-2M signal over the triplicate samples and
its dose-related dependency from drug concentration conﬁrmed
low RNA contents being caused by drug toxicity rather than poor
test performance. Inter-replicate variation >3 Ct values for either
Leishmania 18S or b-2M ampliﬁcation was considered indicative
of poor RNA quality or extraction performance, resulting in the
exclusion of these samples.
2.6. Data analysis
The inhibition of parasite growth was determined by comparing
the amount of viable parasites detected in the drug-treated sam-
ples with that of the untreated controls. Non-linear regression
analysis (Graph-Pad Software Inc., San Diego, USA) was used for
curve ﬁtting and calculation of 50% inhibitory concentrations
(IC50). The relationship between the two assays was studied by
use of the individual logIC50 values. Correlation between data ob-
tained with the two assays was assessed by the Pearson’s correla-
tion test, while the Bland and Altman plot was used to study the
level of agreement between the two methods and to show disper-
sion of data (Bland and Altman, 1986).
3. Results
3.1. Performance of the duplex qRT-PCR
The qRT-PCR targeting the Leishmania 18S rRNA has previously
been validated for quantiﬁcation of Leishmania parasites (van der
Meide et al., 2005). The standard curve for ampliﬁcation was linear
over a 6-fold log10 range of Leishmania donovani 1S RNA.
In the present study, a dilution series of Trizol-extracted RNA
from Leishmania donovani 1S promastigotes was used as a standard
for the duplex qRT-PCR in a background of 100 ng of THP-1 cell
RNA extract, which corresponds to the average amount of human
RNA found in each micro-titer well seeded with Leishmania
amastigotes. The Leishmania 18S ampliﬁcation reaction wasFig. 1. Duplex qRT-PCR targeting the Leishmania 18S rRNA (in blue) and the human b-2
Leishmania 18S ampliﬁcation reaction (B) for a dilution series of Leishmania donovani 1S
Modest reduction of b-2M ampliﬁcation (red curves 1–2) was observed in the presen
references to colour in this ﬁgure legend, the reader is referred to the web version of thconﬁrmed linear with a correlation coefﬁcient of 0.995 over the
range of 1 ng to 1 fg RNA, corresponding to 10,000–0.01 parasites
(Fig. 1A, blue curves, and Fig. 1B). To exclude that sensitivity of
the Leishmania 18S-PCR could be negatively affected by competi-
tion for b-2M ampliﬁcation, the standard samples were tested with
and without b-2M primers in the PCR mix. Comparison of the two
reaction mixes showed equally good ampliﬁcation of Leishmania
18S for all standard samples, with no loss of sensitivity due to com-
petition for b-2M ampliﬁcation (data not shown). The b-2M mRNA
signals derived from ampliﬁcation of background THP-1 cell RNA
in the standard samples were all comparable (Ct values ranging
from 23.3 to 23.7), regardless of the amount of Leishmania RNA
present (Fig. 1A, red curves). Only the standard samples with the
highest parasite content (1 ng and 100 pg parasite RNA) showed
slightly reduced ampliﬁcations of b-2M (Ct values of 25.6 and
24.1, respectively), due to internal competition (Fig. 1A, red curves
1–2).3.2. Pharmacological validation
To validate the use of the qRT-PCR for assessment of drug efﬁ-
cacy against Leishmania intracellular amastigotes, the PCR assay
was compared with standard microscopy by a blind, side-by-side
evaluation. A set of 10 compounds marked by different potencies
and mechanisms of action was used to validate the performance
of the duplex qRT-PCR. The compound panel included a series of
protein kinase-, protein transporter- and phosphodiesterase-inhib-
itors (Orrling et al., 2012). Next to these compounds, three refer-
ence anti-leishmanial drugs were also assessed in the developed
assay. A high correlation was found between the parasite load esti-
mated by qRT-PCR and microscopy counting, regardless of which
compound and concentration the parasites were exposed to
(Fig. 2 and Table 1). The IC50 values yielded by the two assays dur-
ing two independent experiments showed good agreement for
most of the compounds tested (Table 1). Few discrepancies were
observed (imipramine, VUF11852 and VUF11856), in which either
the qRT-PCR or the microscopy data were marked by poor repro-
ducibility with the replicate experiment. The Pearson’s correlation
test conﬁrmed a signiﬁcant correlation between the log IC50 values
obtained by the two assays (r = 0.95, n = 21, P <0.0001) (Fig. 3A). In
the Bland and Altman plot (Fig. 3B), the mean difference in the-microglobulin mRNA (in red): ampliﬁcation curves (A) and linearity range of the
RNA ranging from 1 ng (1) to 1 fg (7) in a background of 100 ng of THP-1 cell RNA.
ce of 1 ng and 100 pg of Leishmania RNA, respectively. (For interpretation of the
is article.)
Fig. 2. Drug dose–response curves of Leishmania donovani 1S intracellular amastigotes, as measured by the qRT-PCR assay (closed circles) and standard microscopy (open
circles). Values are normalized by use of the upper and the lower best-ﬁt values as 100% and 0% responses, respectively, and plotted as the means ± standard errors of the
means of three replicates for the qRT-PCR assay and two replicates for microscopy. Representative data of one out of two experiments are shown.
Table 1
Comparison of IC50 values (lM) of test drugs against Leishmania donovani 1S
intracellular amastigotes, as measured by the qRT-PCR and microscopy in two
independent experiments. Data are shown with three signiﬁcant digits.
Test compounds qRT-PCR (lM) Microscopy (lM)
Exp. 1 Exp. 2 Exp. 1 Exp. 2
Amphotericin B 0.0590 0.233 0.0200 0.180
Miltefosine 1.19 0.639 0.820 0.590
Paromomycin 81.8 53.4 41.9 112
H-89 10.8 6.90 14.6 9.92
Imipramine 25.6 5.50 17.8 19.1
VUF 11852 21.0 27.6 8.93 31.6
VUF 11854 15.0 13.3 13.5 16.7
VUF 11856 4.82 27.8 20.6 40.9
VUF 11857 4.39 5.88 6.21 7.95
VUF 13577 6.70 9.01 7.34 7.05
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microscopy was 0.03 (limits of agreement 0.30 and 0.24). No
tendency for a greater or smaller difference between the two
methods was shown as the IC50 values increased.
The mean Ct value for b-2M ampliﬁcation ranged from 24.5 in
the ﬁrst experiment to 22.7 in the second experiment for untreated
Leishmania-harboring macrophages and uninfected cells. When se-
rial dilutions of the test compounds were incubated with the
Leishmania-infected cells, a dose-related increase in b-2M Ct values
could be observed (Fig. 4), suggesting reduced viability of macro-
phages as a result of drug exposure. The cytotoxic effect displayed
by these compounds and indicated by an at least 10-fold lower
b-2M ampliﬁcation (corresponding to P3 Ct value increase over
the controls) corroborated microscopy observation, whereby poor
or no cell morphology was conﬁrmed (data not shown). Based onthese microscopy observations, a 10-fold lower b-2M ampliﬁcation
was considered indicative of overall cell toxicity.4. Discussion
In vitro amastigote-based assays for screening of novel anti-
leishmanial compounds have been widely recognized as highly
predictive of in vivo drug efﬁcacy, although experimental con-
strains still limit their broad implementation (Gupta and Nishi,
2011). New technologies for improving the quality of these assays
have been developed, including several molecular tools for evalua-
tion of anti-leishmanial drug activities in both in vitro and in vivo
models. The present work describes a further advancement of
these genetic assays, in which viability of Leishmania intracellular
forms, the amastigotes, and their host cells is simultaneously as-
sessed by a duplex qRT-PCR, targeting the Leishmania-speciﬁc
18S rRNA and the human b-2M mRNA, which serves as internal
control for test performance and drug cytotoxicity. Pharmacologi-
cal validation of the assay, performed with a 10-compound set
blindly assessed against standard microscopy, resulted in a good
correlation between anti-leishmanial dose–response curves ob-
tained by the two assays and the corresponding IC50 values, even
when considering the highly subjective and inaccurate nature of
microscopy scoring (Gupta and Nishi, 2011). Duplicate experi-
ments showed fair intra-assay agreement for both PCR and micros-
copy, although for few compounds, a 4- to 5-fold difference in IC50
values was observed, possibly caused by differences in the infec-
tion load. Intra-assay variation of parasite burdens is not uncom-
mon when using this amastigote-macrophage model, as parasites
need to actively enter the host cells and proliferate therein, upon
conversion into amastigotes. This may have important implica-
tions for the IC50 outcome, as conﬁrmed by the critical role played
Fig. 3. (A) Correlation between the logarithm of the individual IC50 values (in lM) measured by the qRT-PCR and the microscopy assays for 10 different compounds (n = 21;
r = 0.95; P <0.0001). (B) Bland and Altman graph of the mean log IC50 values, as determined by qRT-PCR and microscopy for 10 different compounds, plotted against their log
IC50 difference. The estimated mean difference (0.03) and its conﬁdence interval (± 2 standard deviation) are shown as horizontal lines.
Fig. 4. Drug dose–response curves of Leishmania donovani 1S intracellular amastigotes, as measured by the qRT-PCR assay (closed circles, left y axis) and the corresponding Ct
values for b-2M ampliﬁcation (open rhombus, right y axis). Values indicating Leishmania growth (closed circles) are normalized by use of the upper and the lower best-ﬁt
values as 100 and 0% responses, respectively. Data are plotted as the means ± standard errors of the means of three replicates for the qRT-PCR assay and two replicates for
microscopy. Representative data of one out of two experiments are shown.
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ular Leishmania strain they belong to and the cell line bearing the
infection (Seifert et al., 2010).
Compared to alternative drug screening assays, microscopy
counting offers the advantage of enabling host cell morphology
to be visualized, so that both anti-leishmanial activity and drug
cytotoxicity can be simultaneously assessed. In this respect, this
duplex qRT-PCR represents a valuable alternative, as it allows for
simultaneous detection of parasite and cell viability. Substantial
drug cytotoxicity, microscopically conﬁrmed by the poor morphol-
ogy of human macrophages, was detected by the qRT-PCR, which
yielded an at least ten-fold reduced b-2M ampliﬁcation rate as op-
posed to the untreated controls.
Extensive debate on the use of DNA over RNA for drug resis-
tance studies (Reimão et al., 2001; van der Meide et al., 2008;Romero et al., 2010) has resulted in the general belief that DNA re-
mains stable over a long period of time, pending on environmental
conditions, and it is therefore unsuited for testing viability of mi-
cro-organisms, including Leishmania spp. Our preliminary experi-
ments conducted with leishmanicidal doses of amphotericin B
indicated that 18S DNA levels of Leishmania donovani 1S-infected
macrophages differed less than a factor 10 from the untreated con-
trols (data not shown), whereas a 1000-fold difference in 18S rRNA
content was observed when the same samples were assayed by
qRT-PCR and microscopy. Though in agreement with the general
opinion, these ﬁndings contradict what was previously observed
by others, who used real-time PCR to amplify DNA extracts and as-
sess anti-leishmanial drug activity. Gomes et al. (2012) targeted
the Leishmania-18S DNA in a Leishmania infantum amastigote-
mouse model, obtaining amphotericin B IC50 values (0.02 lM) that
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data resulted from a comparable reduction in parasite amount,
however, is unknown since the report does not mention absolute
parasite numbers. Ordóñez-Gutiérrez et al. (2009) were able to
demonstrate by PCR only a 3-fold decrease in Leishmania amasti-
gote DNA content, as opposed to the 10-fold difference observed
by microscopy during exposure to cystatin. Finally, Prina et al.
(2007) also used a DNA-based protocol for testing parasite viability
and thereby demonstrate that Leishmania DNA is rapidly degraded
in vitro following parasite death. These observations, however,
were based on the use of L-Leucine methyl esther only, an experi-
mental drug inducing rapid death of Leishmania mexicana and
Leishmania amazonensis spp. Commercially available anti-leish-
manial drugs, such as those tested in this study, are instead known
to act progressively over a longer period of time (Monzote, 2009),
resulting in potentially different effects on parasite/host cell viabil-
ity and corresponding metabolisms. Furthermore, the use in the
three above-mentioned studies of mouse cells as a macrophage
source rather than the human THP-1 cell line employed here,
may partially account for the discrepancies observed, given that
profound differences between rodent and human macrophages
have been described (Murray and Wynn, 2011).
The present study was conducted on a selection of compounds,
for which comparable anti-leishmanial activities were obtained by
qRT-PCR and microscopy. Further evaluation of the assay is now
required to establish its performance with different Leishmania
models and testing compounds. Efforts to automatize the tech-
nique are also equally crucial to ensure this qRT-PCR may be suit-
able for high-throughput drug screening. Accurate RNA isolation is
key to this assay, but several automated RNA extraction systems
capable of yielding high-quality RNA are nowadays available on
the market. This opens important avenues for the further develop-
ment of this assay.
In conclusions, the present results demonstrate the value of this
qRT-PCR as a sensitive and reliable tool for assessing drug activities
against Leishmania intracellular amastigotes and their host cells,
simplifying the use of the clinically relevant stage of leishmaniasis
for drug discovery programs.
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